MOROXYDINE HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H13N5O.ClH
Molecular Weight	207.661
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

Cl.NC(=N)NC(=N)N1CCOCC1

InChI

InChIKey=FXYZDFSNBBOHTA-UHFFFAOYSA-N

InChI=1S/C6H13N5O.ClH/c7-5(8)10-6(9)11-1-3-12-4-2-11;/h1-4H2,(H5,7,8,9,10);1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H13N5O
Molecular Weight	171.2003
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Moroxydine is an antiviral drug discovered in the 1950’s which was shown to be active against DNA and RNA viruses. Moroxydine analogues are potent anti-hepatitis C virus (HCV) agents.

Originator

Approval Year

Conditions

Conditions

Condition	Modality	Targets	Highest Phase	Product
Viral infection 4	Primary		Approved 8,583	VIRULEX FORTE

Doses

Show entries

Dose	Population	Adverse events
0.04 g/kg 1 times / day steady, Studied dose	unhealthy	Disc. AE: Diarrhea, Itching...

Showing 1 to 1 of 1 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Itching	1 patient Disc. AE	0.04 g/kg 1 times / day steady, Studied dose	unhealthy
Diarrhea	2 patients Disc. AE	0.04 g/kg 1 times / day steady, Studied dose	unhealthy

Showing 1 to 2 of 2 entries

Previous1Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2,252	inhibitor 2,438	inhibitor 2,507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2,057 CYP1A2 2,153	P-gp 2,052

Drug as perpetrator

Show entries

Target	Modality	Activity
CYP1A2 2,333	inhibitor 4,027	no [IC50 >10 uM]
CYP2C19 2,141	inhibitor 4,027	no [IC50 >10 uM]
CYP2C9 2,497	inhibitor 4,027	no [IC50 >10 uM]
CYP2D6 2,546	inhibitor 4,027	no [IC50 >10 uM]
CYP3A4 2,633	inhibitor 4,027	no [IC50 >10 uM]

Showing 1 to 5 of 5 entries

Previous1Next

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2,052	substrate 4,014	no

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

Daily dose ranges from 25 to 5600 mg.

Route of Administration: Other

In Vitro Use Guide

6.3 μg/mL Moroxydine suppresses apoptosis in grass carp reovirus (GCRV)-infected Ctenopharyngodon idella kidney (CIK) cells.

Substance Class	Chemical
Record UNII	6Y9698W0XT
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

MOROXYDINE HYDROCHLORIDE

Common Name

English

NSC-407204

Preferred Name

English

NSC-47838

Code

English

NSC-63755

Code

English

NSC-43840

Code

English

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

NSC

63755

PRIMARY

NSC

52355

PRIMARY

FDA UNII

6Y9698W0XT

PRIMARY

EPA CompTox

DTXSID1045376

PRIMARY

CAS

3160-91-6

PRIMARY

Showing 1 to 5 of 15 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					O611591WAH

MOROXYDINE

PARENT -> SALT/SOLVATE

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					O611591WAH

MOROXYDINE

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Conditions

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

PubMed

Patents

Sample Use Guides

Drug as perpetrator